We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Committee Backs Horizon’s BLA for Thyroid Eye Disease
FDA Advisory Committee Backs Horizon’s BLA for Thyroid Eye Disease
The FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee voted unanimously on Friday to support Horizon Pharma’s teprotumumab infusion to treat active thyroid eye disease (TED).